• Calumet, Inc. reported past second-quarter 2026 results with sales of US$1,445.1 million versus US$1,026.6 million a year earlier, and a net loss of US$95.9 million versus US$147.9 million, alongside wider six‑month losses despite higher year‑to‑date sales.
• The combination of stronger quarterly revenue, a smaller quarterly loss, and a larger year‑to‑date loss gives investors a mixed picture of Calumet’s progress on profitability and operational momentum.
• Next, we’ll examine how higher quarterly sales alongside a reduced quarterly net loss fit into Calumet’s existing investment narrative and outlook.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Calumet Investment Narrative Recap

To own Calumet, you need to believe that its shift toward renewables and higher value specialty products can eventually offset current losses and balance sheet pressure. The latest quarter’s higher sales and narrower quarterly loss are encouraging, but the larger six month loss keeps profitability and cash generation as the key near term catalyst, while high leverage and negative equity remain the biggest risk. This earnings release does not fundamentally change that risk balance.

Among recent announcements, Calumet’s July 2026 redemption of US$100.0 million of 9.75% senior notes stands out alongside these results. Retiring this expensive debt modestly reduces future interest costs and slightly eases balance sheet strain, which ties directly into the near term catalyst of improving cash flow and the risk that refinancing costs stay elevated. Combined with the extended ABL facility, it shows Calumet is actively reshaping its capital structure as it works through continued net losses.

Yet behind the revenue gains, the combination of higher year to date losses and ongoing dependence on favorable renewable fuel policies is exactly where investors should be especially alert to...

Calumet's narrative projects $5.3 billion revenue and $226.9 million earnings by 2029. This requires 8.6% yearly revenue growth and a $415.7 million earnings increase from -$188.8 million today.

Uncover how Calumet's forecasts yield a $38.80 fair value, in line with its current price.

Exploring Other Perspectives

Compared with the baseline view, the most pessimistic analysts focus on regulatory and financing risks, even while assuming revenue of about US$4.2 billion and earnings of roughly US$142 million by 2029.

Explore 2 other fair value estimates on Calumet - why the stock might be worth just $38.80!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Calumet research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Calumet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Calumet's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.